StockData
Pelthos Therapeutics Inc. logo

Pelthos Therapeutics Inc. (PTHS) stock

PTHSNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$7.10+0.26 (+3.80%)

Close on Nov 18, 2026Market cap $27.18MP/E –Yield –

Pelthos Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Pelthos Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$57.78M. For fiscal 2025 it was -$32.43M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$32.43M–
FY2024Dec 31, 2024-$7.57M–
FY2023Dec 31, 2023-$6.86M–
FY2022Dec 31, 2022-$2.32M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$17.32M–
Q1 FY2026Mar 31, 2026-$13.09M–
Q4 FY2025Dec 31, 2025-$12.00M–
Q3 FY2025Sep 30, 2025-$15.36M–
Q2 FY2025Jun 30, 2025-$3.23M–
Q1 FY2025Mar 31, 2025-$1.83M–
Q4 FY2024Dec 31, 2024-$1.82M–
Q3 FY2024Sep 30, 2024-$2.05M–
Q2 FY2024Jun 30, 2024-$1.76M–
Q1 FY2024Mar 31, 2024-$1.93M–
Q4 FY2023Dec 31, 2023-$3.88M–
Q3 FY2023Sep 30, 2023-$1.29M–
Q2 FY2023Jun 30, 2023-$777.16K–
Q1 FY2023Mar 31, 2023-$914.58K–

More Pelthos Therapeutics figures

See a number that looks wrong?